Subscribe
byemo-shutterstock-com-handshake-
ByEmo / Shutterstock.com
19 January 2017Americas

Biogen to pay $1.25bn to Forward Pharma in licensing deal

Biogen and Forward Pharma, a Denmark-based company, have entered into a settlement and licensing agreement under which Biogen will pay Forward Pharma $1.25 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Biogen fights off Mylan’s Tecfidera patent challenge
6 February 2020   US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.
Americas
Forward Pharma files opening brief against PTAB Biogen decision
7 September 2017   Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).
Americas
Biogen asks district court to dismiss competition complaint by Ixchel
26 May 2017   Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Big Pharma
Biogen fights off Mylan’s Tecfidera patent challenge
6 February 2020   US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.
Americas
Forward Pharma files opening brief against PTAB Biogen decision
7 September 2017   Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).
Americas
Biogen asks district court to dismiss competition complaint by Ixchel
26 May 2017   Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.

More on this story

Big Pharma
Biogen fights off Mylan’s Tecfidera patent challenge
6 February 2020   US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.
Americas
Forward Pharma files opening brief against PTAB Biogen decision
7 September 2017   Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).
Americas
Biogen asks district court to dismiss competition complaint by Ixchel
26 May 2017   Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits